Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Trial of Neoadjuvant Docetaxel Plus Cisplatin and 5-Fluorouracil Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

Next Previous
Trial Profile

Randomized Phase II Trial of Neoadjuvant Docetaxel Plus Cisplatin and 5-Fluorouracil Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi

Most Recent Events

  • 09 Jul 2008 Final results reported at ASCO 2008 (1113304).
  • 14 Dec 2006 Status change
  • 14 Sep 2006 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top